The U.S. FDA has indicated support for an accelerated approval pathway for Mesoblast Limited's rexlemestrocel-L, a treatment for end-stage ischemic heart failure patients with a left ventricular assist device (LVAD). This follows positive results from a pivotal study showing significant benefits, including reduced mortality and improved ability to wean off LVAD support. Mesoblast plans to request a pre-Biologics License Application meeting with the FDA to discuss further steps towards approval.